ABT•benzinga•March 24, 2025 at 01:03 PM

Abbott Laboratories Announces That The FDA Has Approved An Investigational Device Exemption For Its Coronary Intravascular Lithotrips System To Evaluate The Treatment Of Severe Calcification In Coronary Arteries Prior To Stenting

No summary available.

Read the full article from the original source for complete details and context.

Article published on March 24, 2025 by benzinga